Passage Bio Announces 2026 Annual Meeting Results and Director Elections

On May 19, 2026, Passage Bio, Inc. held its 2026 Annual Meeting of Stockholders. During the meeting, stockholders voted on four key proposals. First, Athena Countouriotis, M.D., and Sandip Kapadia were elected as Class III directors to serve three-year terms expiring at the 2029 Annual Meeting. Second, the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Third, stockholders approved, on a non-binding advisory basis, the compensation of the company's named executive officers. Finally, stockholders expressed a preference for holding future advisory votes on executive compensation every year. Following this recommendation, the Board of Directors determined that the company will conduct such advisory votes annually until the next required stockholder vote on frequency. The filing confirms the results for each proposal, including total shares for, against, withheld, and broker non-votes.